Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Apr;128(4):521-529.
doi: 10.1007/s00702-021-02339-7. Epub 2021 Apr 20.

Dystonia and leveraging oral pharmacotherapy

Affiliations
Review

Dystonia and leveraging oral pharmacotherapy

Michelle Ann C Sy et al. J Neural Transm (Vienna). 2021 Apr.

Abstract

Dystonia is a clinically diverse disorder, characterized by sustained or intermittent muscle contractions causing abnormal and often repetitive movements and/or postures. Accurate clinical diagnosis is tantamount to effective dystonia management. Current guidelines in the treatments of dystonia, including oral therapy, are prescribed to improve symptoms and to restore functional capacity. Identifying treatable causes from co-existing phenomenologies is relevant to provide the most optimal and disease-specific medications. In other forms of dystonia, genetic factors may affect outcome. Moreover, proper selection of patients, early initiation of medications and customized drug titration are keys to increasing the chances of success when using oral therapies for dystonia. Treatment of dystonia primarily involves agents that target dopamine and acetylcholine receptors. Other drugs used include benzodiazepines, baclofen, antiepileptics, some antipsychotics drugs and antihistamine, with different levels of evidence of effectiveness. Unfortunately, most of the widely used drugs have low levels of evidence and are primarily based on anecdotal experiences. Finally, other adjunctive therapeutic strategies are often necessary to complement oral therapy.

Keywords: Dystonia; Genetic; Management; Pharmacotherapy; Treatment.

PubMed Disclaimer

References

    1. Adler A, Peselow E, Rotrosen J, Duncan E, Angrist B (1993) Brief reports vitamin. Biol Psychiatry 9:1405–1407
    1. Adler LA, Edson R, Lavori P, Peselow E, Duncan E, Rosenthal M et al (1998) Long-term treatment effects of vitamin e for tardive dyskinesia. Biol Psychiatry 19:134–138
    1. Albanese MA, Barnes MP, Bhatia KP, Fernandez-alvarez E (2006) A systematic review on the diagnosis and treatment of primary (idiopathic) dystonia and dystonia plus syndromes: report of an EFNS/MDS-ES Task Force. Eur J Neurol 26:433–444
    1. Albanese A, Asmus F, Bhatia KP, Elia AE, Elibol B, Filippini G et al (2009) EFNS guidelines on diagnosis and treatment of primary dystonias. Eur J Neurol 1:5–18
    1. Albanese A, Di Giovanni M, Lalli S (2019) Dystonia: diagnosis and management. Eur J Neurol 26(1):5–17 - PubMed

LinkOut - more resources